AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Nexalin’s Digital Health Acquisition Shows Neurostimulation Is Going AI-Native
Nexalin’s acquisition of a digital health platform suggests the company is trying to pair neurostimulation with AI-driven software capabilities. The deal reflects a larger trend: device companies are increasingly buying digital infrastructure to deepen product differentiation and data access.
AI Is Moving From the Clinic to the Marketplace as Medtech Sales Pitch Shifts
Modern Healthcare reports that medtech companies are increasingly selling providers on AI rather than just hardware or software features. That change suggests AI has become a competitive baseline in healthcare procurement, not a niche differentiator.
How Bunkerhill Health’s CMS Win Signals a New Business Model for AI Cardiology
Bunkerhill Health has secured CMS payment for its AI-based cardiac analysis, a milestone that matters as much for reimbursement as for technology. The decision suggests AI tools are moving from pilot projects into the messy but crucial economics of routine care.
WellSky’s AI Scribe Win Shows Ambient Listening Is Now a Serious Home Care Category
WellSky has won a MedTech Breakthrough award for its AI-powered ambient listening and transcription tools in home healthcare. The recognition suggests the ambient AI market is expanding beyond hospitals and clinics into the more fragmented world of home-based care.
Eko Adds a New Clinical Heavyweight as Cardiac AI Moves Toward Mainstream Practice
Eko Health has appointed Dr. Steven Steinhubl as chief medical officer, adding a recognized digital health leader to its leadership bench. The hire suggests the company is preparing for a more clinically rigorous phase of growth as cardiac AI moves closer to routine care.
Digital health awards highlight how fast the market is professionalizing
MedTech Breakthrough’s 10th annual awards point to a digital health market that is moving from experimentation toward category formation. The annual recognition program also reflects how much the sector now values product maturity, clinical utility, and operational fit.
Eko Adds a New Clinical Heavyweight as Cardiac AI Moves Toward Mainstream Practice
Eko’s appointment of Dr. Steven Steinhubl as CMO signals that cardiac AI is entering a more clinical, evidence-driven phase. The hire suggests the company is prioritizing validation, deployment strategy, and global adoption over pure product hype.
Airway Medical’s Drug-Coated Balloon Wins FDA Breakthrough Designation
The FDA has granted breakthrough device designation to Airway Medical’s pulmonary drug-coated balloon, giving the company a potentially faster path through development. The designation also highlights continued interest in interventional technologies for challenging pulmonary conditions.
Medtronic Lands on TIME100 as Investors Watch Its AI-Driven Innovation Strategy
Medtronic’s appearance on the TIME100 Companies list highlights how deeply innovation has become tied to digital and AI-enabled medtech strategies. The recognition also underscores how large device companies are being evaluated not just on scale, but on their ability to convert technology into clinical momentum.
Medtech Compliance Is Becoming a Platform Problem, Not a Paper Problem
Enlil and OVA Solutions have formed an alliance aimed at closing documentation gaps in medtech compliance. The partnership reflects a broader shift toward integrated compliance platforms as manufacturers try to keep pace with increasingly complex regulatory demands.
Compliance Before AI: Why Medtech Companies Are Being Told to Build the Foundation First
A new industry reminder argues that medtech companies should strengthen compliance foundations before layering on AI tools. The message reflects a broader shift in the market: organizations with weak governance are discovering that AI amplifies existing problems instead of fixing them.
Orchestra BioMed Gets Another FDA Breakthrough Device Tag for AVIM Therapy
The FDA granted Orchestra BioMed an additional Breakthrough Device Designation for AVIM therapy, extending regulatory momentum for the cardiovascular technology. The designation may help streamline development and communication with regulators, but it does not substitute for clinical proof.
Philips pushes for proof, scale, and sharing as healthcare AI enters its commercialization phase
Philips is emphasizing evidence generation and replication as the healthcare AI market matures. The message is that vendors will increasingly be judged on demonstrated outcomes, not just technical novelty.
Butterfly's FDA AI Clearance Sets Up a Key Earnings Test for Medtech AI
Butterfly Network is heading into earnings after receiving FDA clearance for an AI tool, giving investors a fresh test of whether regulatory wins can translate into revenue. The clearance adds momentum to the company's strategy of pairing portable imaging hardware with software-driven differentiation.
AdvaMed Signals the Medtech Industry Wants a Bigger Voice in AI and Digital Health
AdvaMed’s new AI and digital health insight series suggests the medtech sector is trying to shape the policy and commercial agenda around healthcare AI. The industry knows the next phase of AI adoption will be defined as much by regulation, interoperability, and reimbursement as by model performance. The move is a sign that device makers want to be seen not just as hardware vendors, but as key infrastructure providers in digital care.
Medical Device Cybersecurity and Innovation Keep Converging at the Same Summit
AdvaMed's cybersecurity summit underscores how device security has become a core issue in medical technology, not a niche compliance function. As AI-enabled devices proliferate, security, reliability, and regulatory readiness are becoming inseparable from innovation strategy.
How to Build a Better Regulatory Path for Breakthrough Noninvasive Devices
A startup-focused piece from Medical Design & Outsourcing highlights the practical regulatory lessons emerging from a breakthrough noninvasive device company. The story is useful because it reflects how early-stage medtech firms increasingly have to treat regulatory strategy as a product design discipline.
Startup Funding Highlights the Next Frontier in Bone Health Wearables
Osteoboost has raised $8 million to expand access to its FDA-cleared prescription wearable for bone health. The funding underscores investor interest in consumer-friendly devices that sit between medical treatment and long-term disease management.
FDA Guidance Changes Put Medtech AI Teams on Notice
A new industry analysis says FDA’s AI device guidance is evolving in ways that will force medtech companies to tighten documentation, monitoring, and change management. The underlying message is clear: AI products will be judged less like static tools and more like living systems.
Heartflow’s Patent Fight Suggests Imaging AI Competition Is Entering a New Phase
Heartflow is suing a competitor over alleged patent infringement, a sign that imaging AI rivalry is becoming more legal and less purely technical. As the market matures, intellectual property may shape who can scale, partner, or defend a product line.
FDA Draws a Harder Line on AI Software as Medtech Pushes Back
Two new takes on the FDA’s evolving AI posture underscore a central tension in digital health: regulators are trying to apply legacy device frameworks to software that updates continuously and learns over time. The result is a widening gap between how AI is built and how it is governed.
AdvaMed warns fragmentation is medtech’s biggest threat as the sector becomes more software-driven
AdvaMed is arguing that fragmentation, not lack of innovation, has become medtech’s central strategic risk. The warning reflects an industry increasingly constrained by disconnected data, siloed workflows, and uneven policy frameworks just as devices become more software-intensive and care pathways more integrated.
GE HealthCare and Stanford Deepen AI Imaging Partnership, Hinting at a New R&D Model for Radiology
GE HealthCare and Stanford are expanding their AI imaging collaboration, a sign that the next phase of radiology AI may be built through closer ties between industry and academic medicine. The partnership suggests vendors are looking beyond one-off algorithms toward longer-term product pipelines.
FDA and UK Strengthen MedTech Regulatory Partnership as Global Harmonization Gains Pace
The UK and US are deepening cooperation on medical technology regulation, a move that could make it easier for device makers to navigate approvals across major markets. The development reflects a broader push toward regulatory alignment in an industry increasingly shaped by software and cross-border evidence generation.
FDA and Industry Reach MDUFA VI Framework Deal, Setting the Tone for Device Review Through 2031
FDA and medtech industry negotiators have reached an agreement in principle on the next Medical Device User Fee Amendments framework. The package will shape review resources, performance goals, and likely the operational environment for AI-enabled devices over the next cycle.
AI in Device Manufacturing Is Becoming a Quality-System Problem, Not Just an Efficiency Opportunity
A new industry analysis on AI integration in medical device manufacturing highlights a shift from experimentation to quality-system accountability. As AI moves into design, production, and quality workflows, medtech companies must treat it as part of regulated operations rather than a generic productivity tool.
AdvaMed’s digital health push shows industry lobbying is moving from access to AI rules of the road
AdvaMed’s latest focus on AI and digital health reflects how medtech trade groups are shifting from innovation cheerleading to shaping implementation frameworks. The policy battleground is increasingly about evidence expectations, reimbursement logic, and operational standards for software-based medicine.
FDA’s New Weight-Loss Device Guidance Raises the Bar for Obesity Medtech
The FDA has finalized guidance for weight-loss devices, giving manufacturers a clearer regulatory roadmap as obesity treatment expands beyond drugs. The document matters because it signals how the agency expects companies to frame safety, effectiveness, and risk-benefit in a market increasingly shaped by GLP-1 therapies.
Thailand’s Push for International AI Device Standards Reflects a Global Convergence Trend
Thailand is working to ensure AI medical devices align with international standards, signaling how regulators outside the US and Europe are accelerating their frameworks. The move matters because global medtech companies increasingly need interoperable regulatory strategies rather than market-by-market improvisation.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.